Nara Dashdorj
@naradashdorj
Onom Foundation
ID: 2502703683
http://eleg.mn/ 22-04-2014 22:29:22
6,6K Tweet
2,2K Takipçi
2,2K Takip Edilen
🔥off the press: Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Annals of Oncology doi.org/10.1016/j.anno… 👉get the lastest update on HCC management 👉Multiple options > MDT is key ESMO - Eur. Oncology EASL Education ILCA #livertwitter
Princeton University Ludwig Princeton University Associate Director Eileen P. White, PhD discusses the importance of the clinical component connection of Ludwig’s mission to advance the prevention and control of cancer. #CancerResearch youtu.be/L5xLxO7qAAI
It's pleasure coauthoring this Cancer Cell commentary with 2 talented drug development fellows #gregoire marret and #mercedes herrera Princess Margaret Cancer Centre - "Turning the Kaleidoscope: Innovations shaping the future of clinical trials design" authors.elsevier.com/a/1kljp5TA51lC…
Of >105,000 participants with 30-year follow-up, only 9.3% achieved healthy aging (age 70, w/o any chronic diseases). Their diet was significantly associated with this outcome🧵 Nature Medicine
Brain mitochondria are gorgeous! 🥹 Beautiful MitoBrainMap v1.0 collaboration with neuroanatomist, neuropsychologist, and white matter expert Michel Thiebaut de S
📣 ESMO Living Guideline on Hepatocellular Carcinoma: 👉 New title with the latest recommendations and algorithms in an interactive format. #ClinicalPracticeGuideline Arndt Vogel 🔗 ow.ly/CHpJ50VHbYg
Long-term outcomes and OS for zanidatamab + CTx in HER2+ mGEA: 4-year follow-up #ASCO25 🔎Phs-2 👉ORR 76 %m DoR 18.7 mo 👉mPFS 12.5 mo 👉mOS 36 mo 👉Manageable safety 👉95% concordance btw ctDNA & IHC 🧐 strong efficacy signal, phase-3 data awaited ESMO - Eur. Oncology